Mario Cioce

Fixed-term researcher type A MED/04 - GENERAL PATHOLOGY with extensive translational research experience abroad (including covering university roles) and significant clinical and preclinical research experience in the pharmaceutical field.

TRAINING

12/ 2001 PhD in Life Sciences at the Open University London, UK and the European Institute of Oncology, Milan

07/1997 Degree in Medicine and Surgery (110/110 cum laude) University of Naples "Federico II", Naples. Qualification obtained.

WORKING EXPERIENCE

01/09/2020 to date RTDA of General Pathology and Physiopathology at the Campus-Biomedico University, Faculty of Medicine and Surgery, Rome

01/10/2018 - 30/8/2020 Medical Director | TESARO-GSK Italy

12/06/2017 - 28/09/2018 Clinical Research Physician and In-Licensing Consultant | Menarini Ricerche SpA, Florence

18/05/2015 - 09/06/2017 Senior Researcher | Regina Elena National Cancer Institute, Rome

10/09/2012 - 15/05/2015 Assistant Professor of Research | New York University School of Medicine, New York, United States

01/09/2013-01/05/2015: Associate Member of the NYU Clinical Trial Center.

01/12/2011 - 07/09/2012 Instructor | Albert Einstein College of Medicine, Bronx, NY, USA

08/09/2009 - 29/11/2011 Postdoctoral Research Associate | Regina Elena National Cancer Institute, Rome,

01/07/2005 - 03/09/2009: Staff Scientist Preclinical R&D | MSD (Merck Research Laboratories), Rome, Italy

08/01/2002 - 30/06/2005 Postdoctoral Research Associate | University of Dundee/ Wellcome Trust Biocentre, Dundee, UK

11/08/1997 - 03/01/2002 AIRC Research Fellow / PhD Student | European Institute of Oncology, Milan, Italy

ACADEMIC POSITIONS

2022- Teaching General Pathology at the School of Specialization in Clinical Pathology and Clinical Biochemistry, Campus Biomedico University, Rome

2022- Teaching General Pathology and Pathophysiology at the PhD in Integrated Sciences and Bioethics

2020- Teaching General Pathology at the Faculty of Medicine and Surgery, Course: General Pathology and Pathophysiology, Campus Biomedico University, Rome (2 CFU) (Italian language)

2020- Teaching General Pathology and Pathophysiology at the Faculty of Medicine and Surgery, Course: Fundamentals of Medicine III, Faculty of Medicine and Surgery (11 CFU) (English Language)

2020- Tutoring of Genetics and General Pathology at the Faculty of Nutrition Sciences (SANU), Campus Biomedico University, Rome (Italian language)

SCIENTIFIC JOURNALS DIRECTOR

Associate Editor for Frontiers in Cell and Developmental Biology: Cancer Cell Biology

Associate Editor for Frontiers in Cell and Developmental Biology: Cell Death and Differentiation

Member of the editorial board of the Cancer Drug Resistance Journal.

Guest Editor for International Journal of Molecular Sciences (IJMS). Topic "Tumor Secretome".

Guest Editor for “Cancer Drug Resistance”: “Targeting Signaling Pathway to Overcome Drug Resistance for Cancer Therapy.”

Guest Editor for Cancers. Topic "Long Noncoding RNAs in Cancer."

AWARDS

2021: Investigator Sponsored Grant (competitive) from Beigene, USA. Investigating the role of PI3K isoforms in chemoresistance of MPM. €36,000

2015: ICARE-AIRC Reintegration Award Funding: 106.000 euros

2014: NYU Laura and Isaac Perlmutter Cancer Center Developmental Projects Program. Funding: $45.000 NYU Cancer Institute Cancer Center Developmental Project Program (P30CA016087).

2014 Philanthropic Gift from John Rosenwald to NYU Laura and Isaac Perlmutter Cancer Center for the project "Targeting Chemoresistant Tumors: The Key to Transforming Cancer Care" Funding: $1.000.000

2010: Winner of the BEST IDEA AWARD of the Italian Ministry of Health. "A proteomic approach to mesothelioma biology" (Co-PI). Funding: euro 50.000

2004-2005: Wellcome Trust UK Postdoctoral Fellowship.

2002-2004: IARC (International Agency for Cancer) post-doctoral fellowship for two years.

1. Mario Cioce, Andrea Sacconi, Sara Donzelli, Claudia Bonomo, Letizia Perracchio, Mariantonia Carosi, Stefano Telera, Vito Michele Fazio, Claudio Botti, Sabrina Strano, Giovanni Blandino. Breast cancer metastasis: Is it a matter of OMICS and proper ex-vivo models? Computational and Structural Biotechnology Journal, 2022; 20;4003-4008.

2. Cioce M, Rutigliano D, Puglielli A, Fazio VM. Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of Malignant Pleural Mesothelioma cells. Cancer Drug Resist 2022;5:814-28.

3. Donzelli S, Cioce M, Sacconi A, Zanconato F, Daralioti T, Goeman F, Orlandi G, Di Martino S, Fazio VM, Alessandrini G, Telera S, Carosi M, Ciliberto G, Botti C, Strano S, Piccolo S, Blandino G. A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions. Mol Cancer. 2022 Jul 22;21(1):152. (shared first authorship)

4. Cioce M, Sacconi A, Pass HI, Canino C, Strano S, Blandino G, Fazio VM. Insights into Intra-Tumoral Heterogeneity: Transcriptional Profiling of Chemoresistant MPM Cell Subpopulations Reveals Involvement of NFkB and DNA Repair Pathways and Contributes to a Prognostic Signature. Int J Mol Sci. 2021 Nov 8;22(21):12071. (co-corresponding author)

5. Cioce M, Canino C, Pass H, Blandino G, Strano S, Fazio VM. Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma. J Exp Clin Cancer Res. 2021 Nov 2;40(1):344. (co-corresponding author)

6. Cioce M, Fazio VM. EphA2 and EGFR: Friends in Life, Partners in Crime. Can EphA2 Be a Predictive Biomarker of Response to Anti-EGFR Agents? Cancers (Basel). 2021 Feb 9;13(4):700.. (co-corresponding author)

7. Cioce M, Pulito C, Strano S, Blandino G, Fazio VM. Metformin: Metabolic Rewiring Faces Tumor Heterogeneity. Cells. 2020 Nov 9;9(11):2439. (corresponding author)

8. Bruno T, De Nicola F, Corleone G, Catena V, Goeman F, Pallocca M, Sorino C, Bossi G, Amadio B, Cigliana G, Ricciardi MR, Petrucci MT, Spugnini EP, Baldi A, Cioce M, Cortese G, Mattei E, Merola R, Gianelli U, Baldini L, Pisani F, Gumenyuk S, Mengarelli A, Höpker K, Benzing T, Vincenzi B, Floridi A, Passananti C, Blandino G, Iezzi S, Fanciulli M. Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma. Blood Adv. 2020 Nov 24;4(22):5616-5630.

9. Frixa T, Sacconi A, Cioce M, Roscilli G, Ferrara FF, Aurisicchio L, Pulito C, Telera S, Carosi M, Muti P, Strano S, Donzelli S, Blandino G. MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration. Carcinogenesis. 2018;39(2):293-304.

10. di Martino S, Amoreo CA, Nuvoli B, Galati R, Strano S, Facciolo F, Alessandrini G, Pass HI, Ciliberto G, Blandino G, De Maria R, Cioce M. HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. Oncogene. 2018;37(10):1369-85. (corresponding author)

11. Pulito C, Mori F, Sacconi A, Goeman F, Ferraiuolo M, Pasanisi P, Campagnoli C, Berrino F, Fanciulli M, Ford RJ, Levrero M, Pediconi N, Ciuffreda L, Milella M, Steinberg GR, Cioce M, Muti P, Strano S, Blandino G. Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. Cell discovery. 2017;3:17022.

12. Canu V, Sacconi A, Lorenzon L, Biagioni F, Lo Sardo F, Diodoro MG, Muti P, Garofalo A, Strano S, D'Errico A, Grazi GL, Cioce M, Blandino G. MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer. Oncotarget. 2017;8(18):29540-57